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ABSTRACT 
 
Purpose: The purpose of this study was to determine the incidence of 
documented PTSD in adult breast cancer survivors treated at Boston Medical 
Center and the strength of its relationship to important PTSD risk factors. 
 
Methods/Procedures: The cohort was defined retrospectively and a chart review 
was conducted. 
 
Results: The results of the study support that adult breast cancer patients treated 
at Boston Medical Center are at risk for developing PTSD.  Additionally, younger 
and patients with more co-morbidities are at highest risk. 
 
Conclusions: These results underscore the need for both further descriptive 
studies and interventions aimed at early identification and treatment of PTSD in 
breast cancer survivors. 
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INTRODUCTION 
Background:  
Cancer is recognized as the second leading cause of death in the United States8, 
but with improved diagnostic tools and treatment options, many cancers are now 
survivable.  Accordingly, over the last 40 years there has been a dramatic 
increase in the number of cancer survivors.  The National Cancer Institute (NCI) 
estimates that, as of January 2012, there were 13.7 million cancer survivors in 
the United States (representing approximately 4% of the population) (Fig.1).6   
Figure1. Estimated Number of Cancer Survivors in the United States From 1975 to 2012 
 
Source: Mariotto et al 2011. J Natl Cancer Inst 103:117-28.  
 
In addition to the overall increase in survival, the national incidence of cancer is 
anticipated to continually increase over the next 40 years (Fig. 2).  This 
projection is based on a combination of the anticipated population increase and 
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the aging of the baby boom cohort, (i.e. those individuals born between 1946 and 
1964)26 and the US population in general. 
Figure2. Projected number of cancer cases for 2000 through 2050.  
 
 
SOURCE: Hewitt, M. E., Greenfield, S., & Stovall, E. (2006). From cancer patient to cancer 
survivor: lost in transition. Washington, D.C.: National Academies Press. 
 
 
Breast Cancer:  
Aside from skin cancers, breast cancer is the most common cancer diagnosed in 
women living in the United States.25 The American Cancer Society (ACS) 
estimates that close to 300,000 women will be diagnosed with breast cancer 
(including non-invasive and invasive cases) in 2013.25  
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While one in eight women (12%) will develop breast cancer at some point in her 
life, the mortality rates from breast cancer have been declining since 1989; only 
one in thirty-six (3%) women will die from the disease.25 Of note, larger 
decreases in death rates have been seen in women under 50.25  
 
It remains uncertain why there has been a dramatic decrease in breast cancer 
mortality over the past 15 years, but several theories have been proposed.  One 
idea is that there have been significant public health initiatives, such as the 
American Cancer Society’s “Increasing Breast Cancer Screening Initiative”, to 
encourage screening and increased awareness in the past few decades.28 These 
initiatives have resulted in earlier detection, which in turn allow for more 
treatment options and improved survival rates. 
 
Additionally, in 2006 the National Institutes of Health (NIH) published results from 
a large clinical trial that was part of the Women’s Health Initiative (WHI).  The 
WHI was a 15-year research project that combined large randomized controlled 
trials (RCTs) with companion observational studies. The overarching goal of this 
project was to assess potential risk factors for cardiovascular disease, cancer, 
and osteoporosis – three conditions that are the most common causes of death, 
disability, and poor quality of life in post-menopausal women.29 Notably, results 
from the WHI trial which examined combination hormone replacement therapy 
(HRT) suggested that HRT (often used in the prevention and treatment of 
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osteoporosis and the management of symptoms of menopause) may contribute 
to the development of breast cancer among women in this population.30 Given 
the scale of these studies and their visibility, the results were highly influential; 
there was a marked reduction in the use of HRT which could partially explain the 
decrease in breast cancer mortality in subsequent years.31 
 
In addition to reduction in potential risks, there have also been significant 
advances in the treatment of breast cancer since the early 1990’s.  One of the 
most significant pharmaceutical breakthroughs for treatment of HER2/neu-
positive breast cancer (25% of breast cancers58), since the introduction of 
chemotherapy in the 1970’s, resulted from the approval in September 1998 of 
Herceptin® (trastuzumab); a monoclonal antibody.32 The results of early clinical 
trials involving trastuzumab showed that median survival was significantly 
increased from 20.3 to 25.1 months.35 
 
Until the approval of trastuzumab, chemotherapy was the standard of care 
treatment for breast cancer.  Standard chemotherapy is designed to kill cancer 
cells, however, it also damages and kills normal cells in the process.  The 
advantage of trastuzumab was that it was one of the first “targeted therapies” 
designed to only kill or stop the growth of cancer cells, sparing most of the 
normal cells.  By sparing the normal cells, trastuzumab caused fewer side effects 
and became a more attractive treatment option for patients.49 
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More recently, the approval of Perjeta® (pertuzumab), also a monoclonal 
antibody, in June 2012 added an additional treatment option for HER2/neu-
positive breast cancer patients.33  Pertuzumab is also a targeted therapy that 
works together with trastuzumab by killing or stopping the growth of cancer cells 
while also sparing most of the normal cells.50 Clinical trials examining 
pertuzumab in combination with trastuzumab and chemotherapy showed a 38% 
reduction of disease progression or death in breast cancer patients.34, 50   
 
Implications of Survivorship:  
Of the 13.7 million cancer survivors estimated by the NCI to be alive in January 
2012, 22% were diagnosed with breast cancer. (Fig. 3)6   
Figure3. Estimated Number of Persons Alive in the U.S. Who Were Diagnosed With Cancer 
by Site (N = 13.7 M)  [as of January 1, 2012] 
 
Source: Mariotto et al 2011. J Natl Cancer Inst 103:117-28.  
 6 
The NCI estimates that nearly all adults in the United States who are diagnosed 
with Stage I breast cancer will survive five years after diagnosis.  Additionally, 
85.5%, 58.3%, and 18.5% of adults diagnosed with Stage II, II, and IV breast 
cancer respectively, will survive five years after diagnosis.  These survival 
projections appear to hold steady essentially from years six through eight post-
diagnosis.  Notably, those patients diagnosed with Stage IV breast cancer have a 
50% increase in survival 5 years post diagnosis. (Fig. 4) 
 
Figure4. Conditional 5-year relative survival rates, breast cancer, by stage (modified 
American Joint Committee on Cancer [AJCC] staging) 
 
 
 
NOTE: The bars around the point estimates indicate 95 percent confidence intervals 
SOURCE: Hewitt, M. E., Greenfield, S., & Stovall, E. (2006). From cancer patient to cancer 
survivor: lost in transition. Washington, D.C.: National Academies Press. 
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With these improved survival rates, however, new issues for cancer survivors 
must be considered, including adjusting to living life again after being faced with 
a (potentially) life threatening disease.  Of particular importance is consideration 
of a survivor’s quality of life (QOL) not only after diagnosis and during treatment, 
but also once treatment is complete.  In this respect, it is important to consider 
not only the physical well-being, but also the emotional, social, and spiritual well-
being of the cancer survivor as well.16  (Fig. 5)  
 
Figure5. Domains of Quality of Life  
  
 
Source: Adapted from Ferrell et al 1995. Quality of Life Research, 4: 523-531. 
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In order to understand how a disease such as cancer may impact a patient’s 
overall quality of life (QOL), the individual domains of QOL (the physical, 
emotional, social, and spiritual) must be considered.  Physical well-being is 
defined as the degree to which symptoms and side effects, such as pain, fatigue, 
and poor sleep quality, affect the ability to perform normal daily activities.27 
During and immediately after treatment, physical well-being is a clinician’s 
primary concern. Initial breast cancer treatments are tailored to combat the 
physical aspects of the disease, i.e. tumor shrinkage, management of side 
effects, etc.  The goal of treatment is to extend the life and ideally cure the 
patient of the disease.  However, there may be lasting physical effects even after 
treatment is complete.  Survivors may face long-term heart, lung, and kidney 
damage, as well as chronic pain, fatigue, insomnia, cognitive issues, and 
infertility.27 These lasting physical effects may in turn affect the emotional well-
being of the survivor. 
 
Emotional (psychological) well-being as defined is the ability of a patient to 
manage anxiety, depression, fear of cancer recurrence, and problems with 
memory and concentration.27 Coping with a life-threatening illness such as breast 
cancer is emotionally traumatizing to a patient both during and after treatment. 
Anxiety, depression, and memory/concentration issues are also underlying 
symptoms of what is characterized as Post-Traumatic Stress Disorder (PTSD), 
rather than separate co-morbidities.3 Additionally, some of the physical effects, 
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such as fatigue and insomnia, are symptoms that should be considered when 
addressing underlying emotional disturbances resulting from a breast cancer 
diagnosis and treatment.  In fact, insomnia (a sign of hypervigilance, Fig. 6) is a 
common occurrence in cancer survivors who develop PTSD.3 
 
Social well-being, a third and equally important component of QOL in cancer 
patients, involves relationships with family members and friends (including 
intimacy and sexuality), in addition to employment, insurance, and financial 
concerns.27 Importantly, studies have shown that strong social support from 
family and friends have been associated with fewer PTSD symptoms in breast 
cancer survivors.40, 41 This is particularly important as it relates to a patient’s 
spiritual well-being as well. 
 
In cancer patients, spiritual well-being involves drawing meaning from the cancer 
experience, either in the context of religion or by maintaining the spiritual values 
of hope and resilience in the face of uncertainty about one’s future health.27 A 
survivor’s own beliefs and values may prove to be protective.52-55 For example, a 
patient may feel more secure in thinking that “a higher power” is in control when 
everything about his/her future feels uncertain.  Contrary, this way of thinking is 
such that lacking spiritual beliefs and values has the potential to put an individual 
at risk of feeling emotionally unstable.  For example, an individual who does not 
have a solid spiritual belief system may feel more anxious about what the future 
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holds.53  Higher levels of anxiety, in turn, may put an individual’s emotional well-
being at risk, which also may further negatively impact QOL. 
 
Decreasing mortality rates support the need to address the aforementioned 
elements of the QOL for survivors.  Physical well-being is the most obvious 
element of the QOL elements, but clinicians have become increasingly more 
concerned with how the cancer survivor copes emotionally, socially, and 
spiritually.  Treatment for those diagnosed with breast cancer must involve a 
holistic approach that encompasses the four elements of QOL. 
 
As diagnostic criteria and treatment options for breast cancer have markedly 
improved survival, the survivor’s QOL both during and after diagnosis and 
treatment is important and relevant.  While the elements of QOL are intrinsic to 
one another, the focus of the remainder of this paper will be on the survivor’s 
emotional (psychological) and social well-being as it relates to Post-Traumatic 
Stress Disorder.  
 
It is important to note that not all breast cancer survivors report long-term QOL 
issues related to their diagnosis and treatment, but there are many who suffer.  
Studies suggest that those patients who are of minority status (non-whites), are 
of younger age at diagnosis, are of lower socioeconomic status, and who are 
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enduring more invasive and aggressive treatments are at higher risk of 
developing long-term QOL issues.36, 37 
 
Post-Traumatic Stress Disorder (PTSD) Diagnostic Criteria:  
The Diagnostic and Statistical Manual of Mental Disorders (DSM) outlines six 
criteria that must be observed in order for an individual to receive a diagnosis of 
Post-Traumatic Stress Disorder (Fig. 6).11  
 
First, a person must experience a “traumatic event” to which their response must 
evoke intense fear, helplessness, or horror.  The traumatic event is then 
persistently “re-experienced” in at least one of the following ways: recurrent and 
intrusive thoughts or images; recurrent distressing dreams; acting or feeling as if 
the event were recurring; and/or psychological or physiological distress upon 
exposure to reminders of the event. 
 
The individual will typically display avoidance of the stimuli associated with the 
event and numbing of their general response.  This occurs in at least three of the 
following ways: efforts to avoid thoughts, feelings or conversations about the 
event; efforts to avoid activities, places or people that remind the individual of the 
event; inability to remember important aspect(s) of the event (i.e. “traumatic 
amnesia”); significantly diminished interest or participation in activities; feeling 
 12 
detached or estranged from others; having a restricted range of affect; and/or 
speaking or thinking of not having a future. 
 
Additionally, the individual often displays signs of increased arousal that were not 
present before the traumatic event.  This is typically observed in at least two of 
the following ways: trouble falling or staying asleep, irritability or outburst of 
anger, difficulty concentrating, hypervigilance, and/or an exaggerated startle 
response. 
 
Finally, if the individual displays any combination of the aforementioned 
symptoms, in addition to symptoms which last for at least one month, and cause 
significant impairment in daily life, a diagnosis of PTSD should be considered. 
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Figure6. DSM-IV-TR Diagnostic Criteria for PTSD
11 
Criterion A: Exposure to a traumatic event 
1. Response involves intense fear, helplessness, or horror 
Criterion B: Traumatic event is persistently re-experienced in at least one of the following 
ways: 
1. Recurrent and intrusive thoughts or images 
2. Recurrent distressing dreams 
3. Acting or feeling as if the event were recurring 
4. Psychological distress upon exposure to reminders of event 
5. Physiological reactions upon exposure to reminders of event 
Criterion C: Avoidance of stimuli associated with the event and numbing of general response, 
occurring in at least three of the following ways: 
1. Efforts to avoid thoughts, feelings, or conversations about the event 
2. Efforts to avoid activities, places, or people that remind person of the event 
3. Inability to remember an important aspect of the event 
4. Significantly diminished interest or participation in activities 
5. Feeling of being detached or estranged from others 
6. Restricted range of affect 
7. Speaks or thinks of not having a future 
Criterion D: Increased arousal not present before traumatic event, presenting in at least two of 
the following ways: 
1. Trouble falling or staying asleep 
2. Irritability or outbursts of anger 
3. Difficulty concentrating 
4. Hypervigilance 
5. Exaggerated startle response 
Criterion E: Symptoms last at least one month 
 
Criterion F: Symptoms listed above cause significant impairment in daily life 
 
Adapted from American Psychiatric Association. Diagnostic and statistical manual of mental 
disorders, fourth edition, text revision. Washington, D.C.: American Psychiatric Association, 
2000:467–8. Copyright 2000. 
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Prior to the 1994 revision of the DSM, the “traumatic event” referenced in 
Criterion A (Fig. 6) was limited to surviving combat experience (e.g. being 
ambushed by the enemy), terrorism (e.g. bombing a city), natural disasters (e.g. 
flood, fire, earthquake), serious accidents (e.g. car accident), assault or abuse 
(e.g. rape), and/or sudden and major emotional losses (e.g. loss of a child).24 
 
In 1994 the DSM was revised to include the diagnosis of a life-threatening illness, 
such as cancer, as a stressful event that may trigger one to develop PTSD.3, 11 
Since then, it has been well documented that cancer survivors often present with 
symptoms associated with PTSD, such as avoidant behaviors, intrusive thoughts, 
and heightened arousal, following diagnosis and treatment.3   
  
Review of Previous Literature on PTSD:  
Since the fourth revision of the DSM, the lasting psychological effects of 
diagnosis and treatment for breast cancer survivors have been extensively 
researched.6, 13–15 Results have demonstrated that survivors may face profound 
psychological ramifications to living with cancer, such as depression, cognitive 
disorders and delirium, memory changes, and anxiety and distress (including 
Posttraumatic Stress Disorder).11 Among the many psychological issues that may 
result from a cancer diagnosis, PTSD has been widely debated over the past two 
decades.  The NCI estimates that the incidence of PTSD in adult cancer 
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survivors ranges from 3% to 4% in early-stage patients recently diagnosed, to 
35% in patients evaluated after treatment.3 
 
Of note, not all cancer survivors develop PTSD.  There are other factors that may 
play a role in whether or not a cancer survivor may develop PTSD.  Previous 
research demonstrated that sociodemographic, psychosocial, and psychological 
factors may increase the risk of development of PTSD.3   
 
Two separate studies which examined the prevalence and symptom structure of 
PTSD in breast cancer survivors demonstrated that younger patients were more 
prone to developing the disorder than older patients. 38, 39 In these cases, older 
age was a protective factor, perhaps due to survival bias or differences in the 
progression of the disease by age of onset.   
 
Another study assessing women who had completed treatment for breast cancer 
indicated that not only younger patients were at risk, but also those who had 
lower incomes.20 This finding was explained by considering Hobfoll’s “resource 
model”, which proposes that psychological stress (which can manifest as PTSD) 
results from actual or threatened loss of resources.59 In theory, breast cancer 
survivors may incur financial burdens resulting from treatment-related expenses. 
Women with lower incomes may have fewer financial resources to cope with this 
“loss”, which may result in higher levels of psychological stress. 
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Several studies have shown that experiencing traumatic events prior to cancer 
diagnosis and treatment is an important factor related to the future development 
of PTSD.40-44 Interestingly, this was true in both early-stage and metastatic breast 
cancer patients.40, 44 These studies established that previous traumas, such as 
assault and/or combat trauma, combined with recent stressful life events, such 
as a cancer diagnosis, were significantly related to the development of PTSD 
symptoms.  Additionally, those who had pre-morbid psychopathologies (major 
depression, generalized anxiety disorder, alcohol abuse/dependence)45 and 
higher levels of general psychological distress21 were at a greater risk of 
developing PTSD. 
 
Finally, the results of one study focused on social support, specifically the quality 
of the survivor’s recovery environment.  This study demonstrated that lower 
levels of social support were significantly related to the development of PTSD 
even when controlling for other relevant demographic (annual household income, 
education, gender) and medical variables (pre-diagnosis psychiatric history, 
hospitalization status).46 
 
Previous research supports the theory that younger, poorer individuals who lack 
social support and have high levels of general psychological distress, pre-morbid 
psychopathology, and/or a history of previous traumas are at a higher risk of 
developing cancer-related PTSD.  Although prior research has determined that 
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these various factors are associated with an increased risk of developing PTSD, 
it remains unclear as to who may be more susceptible following diagnosis or 
treatment of breast cancer. 
 
Prevalence and Incidence of PTSD in Cancer Survivors:  
The initial research, which pre-dates the DSM-IV, was conducted in the early 
1990’s by Kornblith and colleagues. These early studies examined the levels of 
psychological distress in survivors diagnosed with Hodgkin’s disease.  Although 
these studies did not evaluate the full diagnostic criteria of PTSD, they 
demonstrated that survivors experienced intrusive thoughts and avoidance 
behaviors.13, 14, 17  This was an important finding because when these two key 
diagnostic criteria (intrusive thoughts (Criterion B, Fig. 4) and avoidance 
behaviors (Criterion C, Fig. 4)) were experienced in the context of a “stressor” 
(i.e. cancer), a clinician might begin to suspect PTSD-like symptomology.11  This 
work also suggested that survivors were at higher risk of maladaptive 
psychosocial patterns if they earned less than $15,000 per year, or were 
currently unemployed, unmarried, less educated, and/or had experienced a 
serious illness since completion of cancer treatment.14  These initial observations 
were suggestive of the need for future investigation of these and other potential 
factors that might potentially place a cancer survivor at elevated risk for 
developing PTSD. 
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As such, this work demonstrated that there was a need to investigate PTSD-like 
symptomatology further in cancer survivors.  The first formal study conducted 
using the current DSM-IV diagnostic criteria to examine PTSD in cancer 
survivors was published in 1996 by Alter and colleagues.  The study population 
was comprised of primarily breast cancer patients who were at least 3 years 
post-diagnosis and were no longer receiving any treatment.  The results 
demonstrated that 4% of the patients met diagnostic criteria for current PTSD.4 
 
Subsequent studies involved more formal evaluations of PTSD using self-report 
questionnaires (Impact of Event Scale-Revised [IES-R], the use of PTSD 
Checklist-Civilian [PCL-C]) and structured clinician administered diagnostic 
interviews (Structured Clinical Interview for DSM [SCID]).3, 19 
 
One prospective study used a combination of self-report questionnaires and 
structured clinician administered diagnostic interviews and found that 4% of the 
breast cancer population met DSM-IV criteria for PTSD.19  Whereas, studies that 
have utilized the SCID found that 3% to 10% of the adult cancer patients 
developed cancer-related PTSD.3 
 
Most recently, a prospective cohort study conducted at Columbia University 
Medical Center examined changes in PTSD symptoms in the first six months 
after a breast cancer diagnosis.56 They also assessed racial and ethnic 
 19 
differences in PTSD symptomatology over time.  They found that 23% of newly 
diagnosed breast cancer patients reported symptoms of PTSD, with black and 
Asian women at an increased risk.  The results were made available to the public 
in a press release on February 28, 2013.57 While Columbia University Medical 
Center’s study was systematically different than what is proposed for this project, 
we anticipate similar findings in our results. 
 
Geographic Location of Interest:  
Boston Medical Center (BMC) was chosen for the investigation described in this 
report due to the patient population meeting the criteria for those at risk for PTSD 
and the accessibility of the data. 
 
Boston Medical Center is a tertiary care hospital well-known as the largest safety 
net provider in the New England area.  In 2008, a statement was issued stating 
that Boston Medical Center was “Boston’s largest provider of world class health 
care accessible to all, regardless of status or ability to pay.”7 This was based on 
statistics that demonstrated that over 70% of the patient population at Boston 
Medical Center was from under-served populations, including low income 
families, elders, people with disabilities, minorities, and immigrants.7  
 
As previously noted, this population is intrinsically at risk for developing PTSD 
based on demographics alone.  Additionally, a previous cross-sectional study 
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established that the prevalence of PTSD in the general patient population at 
BMC was 23% (95% CI, 19-26%).60  By adding a breast cancer diagnosis to the 
equation, the incidence of PTSD may likely be higher.  
 
Study Rationale:  
Given the demographics of the BMC patient population and known risk factors 
associated with PTSD, it is possible that adult breast cancer survivors at Boston 
Medical Center may be at a high risk of developing PTSD.  Unfortunately, to 
date, there has been no formal evaluation of this at BMC.  Establishing the 
incidence rate of PTSD in this patient population is important because it would 
provide clinicians at BMC, specifically the mental health professionals, with a 
clearer picture of their patients and which ones may be at risk.  This information 
would enable clinicians to devise more effective and holistic treatment plans by 
considering an atypical condition, such as PTSD, in the mental health differential 
diagnosis.  Furthermore, cancer-related PTSD may prevent survivors from 
achieving optimal quality of life after diagnosis and treatment, and consequently it 
is important for clinicians to be aware of this condition as a potential co-morbidity 
in this patient population. 
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Purpose:  
The purpose of this study was to determine the incidence of PTSD in adult breast 
cancer survivors treated at Boston Medical Center and the strength of its 
relationship to important PTSD risk factors. 
 
Study Questions:  
1. Primary Study Question: Are adult breast cancer survivors treated at 
Boston Medical Center at risk of developing PTSD? 
2. Secondary Study Question: Does age, race, breast cancer stage, and/or 
number of co-morbidities put adult breast cancer survivors (at BMC) at an 
increased risk of developing PTSD? 
 
Objectives: 
1. Primary Objective: Establish the rate of occurrence of new cases of PTSD 
in adult breast cancer survivors treated at Boston Medical Center. 
(incidence) 
2. Secondary Objective: Evaluate the effect of potential predictors/risk 
factors (i.e. age, race, breast cancer stage, and co-morbidities) on the 
outcome. 
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Endpoints/Outcomes of Interest: 
1. Primary Endpoint: incidence of PTSD in adult breast cancer survivors 
treated at Boston Medical Center 
2. Secondary Endpoint: contribution of risk factors (i.e. age, race, breast 
cancer stage, and co-morbidities) to the incidence of PTSD in adult breast 
cancer survivors treated at Boston Medical Center 
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METHODS 
Study Design:  
The study was designed as a retrospective cohort study (Fig. 7). 
 Exposure: breast cancer diagnosis 
 Outcome: post-traumatic stress disorder diagnosis 
 
Figure7. Study Design. 
 
 
 
Materials and Methods:  
Institutional Review Board (IRB) approval was obtained from the Boston 
University Medical Campus IRB prior to initiating any research activities. The 
project investigators did not have access to any identifying information in this 
study.  
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Every individual diagnosed with breast cancer at Boston Medical Center between 
October 1, 2003 and October 1, 2012 was identified through the BMC Tumor 
Registry.10  The following information was collected from the Boston Medical 
Center Tumor Registry: tumor site, stage, date of initial diagnosis (month and 
year). 
 
Information gathered from the Tumor Registry was cross referenced with 
information available in the Boston Medical Center Electronic Medical Record 
(EMR).  All individuals with a breast cancer diagnosis who did not have at least 
one follow-up visit recorded in the EMR were excluded from the study population.  
The EMR was then used to gather the following information: subject 
demographics at time of cancer diagnosis (age, gender, race, and any co-
morbidities), confirmation of diagnosis of breast cancer (ICD-9 code9), 
confirmation that there was at least one follow-up visit recorded in the EMR. 
 
Additionally, all documented cases of PTSD (identified via ICD-9 code) 
diagnosed at BMC between October 1, 2003 and October 1, 2012 were identified 
using the EMR.  Information gathered on these individuals included date of 
diagnosis and age of individual at diagnosis. 
 
All breast cancer cases were then cross-referenced with all PTSD cases that 
were diagnosed at BMC between October 1, 2003 and October 1, 2012.  Any 
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individual with both a breast cancer diagnosis and a PTSD diagnosis was 
identified as part of the cohort.  Those individuals who had a PTSD diagnosis 
that pre-dated the cancer diagnosis were excluded from the analysis. 
 
The “study period” was October 1, 2003 (date EMR system implemented at 
BMC; post DSM-IV publication) through October 1, 2012.10 
 
Subject Population:  
Inclusion Criteria 
 Individuals diagnosed with breast cancer at Boston Medical Center from 
October 1, 2003 through October 1, 2012, and who were 
 at least 18 years of age or older at the date of breast cancer diagnosis, 
and who 
 had at least one follow-up visit recorded in the EMR post breast cancer 
diagnosis. 
 
Exclusion Criteria 
 Breast cancer diagnosis prior to October 1, 2003 or after October 1, 2012, 
and /or 
 age at breast cancer diagnosis is less than 18 years, and/or 
 no follow-up visit recorded in the electronic medical record after the breast 
cancer diagnosis, and/or 
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 diagnosis of Post-Traumatic Stress Disorder (PTSD) before breast cancer 
diagnosis. 
 
Statistical Analysis:  
Unadjusted estimates of incidence were generated using the ratio of the number 
of PTSD diagnoses over total person-years of follow-up. A 95% confidence 
interval was computed to accompany this estimate using the exact Poisson 
method. A simple estimate of the survival experience of subjects following breast 
cancer diagnosis was obtained using the Kaplan-Meier method.51  Mortality and 
subject loss to follow-up were considered censoring events. Comparisons of 
survival according to population subgroups (i.e. comparing women of age 55 
years or younger to those over 55) were obtained using logrank tests. 
 
As it was not clear whether a living subject remained under observation at the 
end of the study period, two analyses were conducted. The primary analysis 
considered subjects to be censored either at their last observed visit to BMC or 
death, if the latter is known. The sensitivity analysis considered at-risk subjects to 
be censored either at the date of death (if known) or October 1, 2012. The 
sensitivity of the incidence estimate to these two approaches is reported in the 
next section. 
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Following unadjusted assessment of survival, the influence of risk factors on time 
to PTSD diagnosis was assessed using Cox proportional hazards regression 
analysis. The significance of individual risk factors was obtained using Wald 
statistics along with chi-square tests derived from analysis of deviance (ANOVA) 
obtained from nested pairs of models. 
 
All analyses were done using the R 2.15.2 statistical environment.23 Results were 
considered statistically significant if null hypotheses could be rejected at the 0.05 
level. 
 
Statistical Power Computation:  
The primary goal of the analysis was to estimate the incidence of PTSD in the 
population of subjects from which the BMC sample was drawn. 
 
There were few existing data concerning incidence of PTSD in breast cancer in 
this population. Based on prior information from the NCI3, it was crudely 
anticipated that approximately 10% of subjects in this population would have a 
diagnosis of PTSD at some point during their post-breast-cancer-diagnosis 
follow-up. As PTSD diagnoses subsequent to diagnosis of breast cancer was of 
most interest, it was more appropriate to consider this analyses as being directed 
at incidence. Based on the numbers above, the best current approximation 
implied 140 new cases of PTSD over between 4000 and 6000 person-years of 
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observation. This would provide an incidence rate estimate somewhere in the 
neighborhood of 28 cases per 1000 person-years (py) of observation (0.028), 
with a precision of approximately 5 cases per 1000 py (0.0047). 
 
While these computations were necessarily inexact, they demonstrated the 
informational value of performing this novel analysis in an understudied 
population. 
 
Risk Factors:   
The following variables were controlled for as potential risk factors by using the 
Cox proportional hazards regression model: age, race, breast cancer stage, and 
comorbidity. The Charlson Index Score was used to quantify comorbidity.22 
Items scored by the Charlson included myocardial infarction, congestive heart 
failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic 
obstructive pulmonary disease, peptic ulcer disease, uncomplicated diabetes 
mellitus, diabetes mellitus with end-organ damage, moderate to severe chronic 
kidney disease, hemiplegia, leukemia, malignant lymphoma, non-metastatic solid 
tumor, metastatic solid tumor, mild liver disease, moderate to severe liver 
disease, and HIV/AIDS.   
 
 29 
Charlson Comorbidity Index Score: 
The Charlson comorbidity index was originally designed to quantify and predict 
the ten-year mortality for an individual who may have various comorbid 
conditions.22  There are 22 conditions that factor into the standardized scoring 
system.  Each of these conditions corresponds with a score of 1, 2, 3, or 6.  The 
assigned score associated with each comorbid condition is determined based on 
the risk of mortality; the highest scores indicate the highest risk of death.  The 
sum of the scores assigned to each of the conditions provides the total score for 
an individual.  This is a well-known method of quantifying co-morbidities.  The 
specific conditions and associated scores are outlined in the Appendix of this 
document. 
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RESULTS 
First, the descriptive information about the baseline characteristics of the study 
population are presented.  Next, the analyses examining the incidence of PTSD 
in the study population and the effects of potential risk factors on the outcome 
are presented. 
 
A general description of the study sample is provided in Table 1.  
 
Table1. Baseline Characteristics.   
 
Cases 
(n = 38) 
Non-cases 
(n= 1263) 
Demographics   
       
a
Age, yr 54 ± 7.03 59 ± 10.87 
       
a
Age, N (%)   
               21-49 yrs 12 (32) 344 (27) 
               49-58 yrs 15 (39) 295 (23) 
               58-68 yrs 9 (24) 308 (24) 
               68-96 yrs 2 (5) 316 (25) 
       Race, N (%)   
               Asian 3 (8) 36 (3) 
               Black/African-American 18 (47) 445 (35) 
               White 16 (42) 639 (51) 
               
b
Other 1 (3) 143 (11) 
a
Primary site, N (%)   
       Breast, axillary tail – 5 (0.4) 
       Breast, central portion – 13 (1) 
       Breast, lower – 1 (0.1) 
       Breast, lower-inner quadrant 1 (3) 69 (5) 
       Breast, lower-outer quadrant 2 (5) 87 (7) 
       Breast, midline of – 6 (0.5) 
       Breast, NOS 12 (32) 390 (31) 
       Breast, outer – 2 (0.2) 
       Breast, overlapping lesion 5 (13) 154 (12) 
       Breast, upper – 1 (0.1) 
       Breast, upper-inner quadrant 5 (13) 124 (10) 
       Breast, upper-outer quadrant 13 (34) 400 (31) 
       Nipple – 11 (0.9) 
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a
AJCC Descriptive Stage, N (%)   
       Stage 0 12 (32) 279 (22) 
       
c
Stage I 9 (24) 394 (31) 
       
d
Stage II 9 (24) 300 (24) 
       
e
Stage III 5 (13) 133 (11) 
       Stage IV – 44 (3) 
       Unknown 3 (8) 113 (9) 
a
Co-Morbidities, N (%)   
       Myocardial Infarction – 51 (4) 
       Congestive Heart Failure 1 (3) 33 (3) 
       Peripheral Vascular Disease – 24 (2) 
       Cerebrovascular Disease 2 (5) 49 (4) 
       Dementia – 6 (0.5) 
       COPD 13 (34) 208 (16) 
       Connective Tissue Disease 3 (8) 20 (2) 
       Peptic Ulcer Disease – 15 (1) 
       Diabetes Mellitus   
              Uncomplicated 13 (34) 209 (17) 
              End-Organ Damage – 32 (3) 
       Chronic Kidney Disease (moderate to severe) 2 (5) 39 (3) 
       Hemiplegia – 3 (0.2) 
       Leukemia/Malignant Lymphoma 1 (3) 16 (1) 
       Solid Tumor   
              Non-Metastatic 38 (100) 1255 (99) 
              Metastatic – 8 (1) 
       Liver Disease   
              Mild – 4 (0.3) 
              Moderate to Severe 2 (5) 15 (1) 
       AIDS 2 (5) 9 (0.7) 
a
Charlson Index Score   
       6 8 (21) 687 (54) 
       7 11 (29) 236 (19) 
       8+ 19 (50) 340 (27) 
   
Note: Percentages are based on total number of subjects in each group. 
a
Measured at initial breast cancer diagnosis 
b
Includes: Middle Eastern, American Indian/Native American, Unknown  
c
Includes: Stage I and Stage IEA 
d
Includes: Stage IIA, Stage IIB 
e
Includes: Stage IIIA, Stage IIIB, Stage IIIC, Stage IIINO 
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Demographic Variables Assessment: 
The total study population was comprised of 1,301 women diagnosed with breast 
cancer.  Of the 1,301 subjects, 38 (3%) had developed PTSD during the study 
period; these subjects were hereafter referred to as PTSD cases.  During the 
pre-defined study period, there were an additional 8 males who were diagnosed 
with breast cancer; however none of them developed PTSD.  Given the small 
number of men, lack of incidence data among them, and the expectation that the 
cancer and PTSD experience may vary by sex, male subjects were thereafter 
excluded. 
  
The age range of individuals contributing data to this report was 21 years to 96 
years (36-84 years for cases; 21-96 years for non-cases).  Of note, 58% of the 
cases, and 50% of non-cases, were identified primarily as a racial/ethnic 
minority.        
 
Etiology of Diagnosis 
The most common site of diagnosis among cases and non-cases was the upper-
outer quadrant of the breast (34% and 31%, respectively). 
 
The distribution of AJCC staging among cases was fairly evenly distributed, with 
32% at Stage 0, 24% at Stage I and Stage II, and 13% at Stage III.  There were 
no individuals diagnosed with Stage IV breast cancer who developed PTSD. 
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The distribution of AJCC staging among non-cases was also fairly evenly 
distributed, with 22% at Stage 0, 31% at Stage I, 24% at Stage II, 11% at Stage 
III, and 3% at Stage IV. 
 
Comorbidity Assessment: (Fig. 8) 
The most prevalent co-morbidities observed in both groups were COPD (34% 
cases, 16% non-cases) and Uncomplicated Diabetes Mellitus (16% cases, 17% 
non-cases). 
 
The range of Charlson comorbidity scores was 6-17.  The lowest total score22 for 
all subjects was 6 (21% cases, 54% non-cases), owing to the fact that each 
subject in the cohort had a diagnosis of breast cancer. 
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Figure8. Prevalence of Co-Morbitities in Study Cohort 
 
Note: 100% of the cohort obviously had “solid tumor”, and 99% of them were “non-metastatic”.  
Additionally, the following conditions had prevalence of <1%: dementia, hemiplegia, and liver 
disease (mild). 
 
 
Primary Analysis:  
The total time contributed to the study (cases + non-cases) was 3,902 person-
years.  The overall incidence of PTSD was 8.46 (95% confidence interval [CI], 
5.98 to 11.62) cases per 1000 person-years of time at risk (Table 2). The 
average time to develop PTSD within the cases was 2.76 years (95% confidence 
interval [CI], CI 0.79 to 4.73). 
 
 35 
In Table 2, unadjusted incidence rates are reported, stratifying according to of 
each of the potential risk factors.  
 
It was observed that, in this sample, younger individuals developed PTSD at a 
higher rate (10.8, CI 6.6 to 16.7) than older individuals (6.8, CI 4.0 to 10.8).  
Considering race, self-identified Asians developed PTSD at a higher rate (24.5, 
CI 5.1 to 71.7) than Blacks (11.2, CI 6.6 to 17.7) and Whites (7.2, CI 4.1 to 11.7). 
 
Individuals with earlier stage cancers (Stage I and Stage II) had a lower 
incidence rate (6.0, CI 2.8 to 11.4 and 7.7, CI 3.5 to 14.6; respectively) than 
individuals with later stage cancers (Stage III, IR: 10.7, CI 3.5 to 14.6).  Of note, 
the earliest stage diagnosis (Stage 0) was correlated with a higher incidence rate 
of 12.3 (CI 6.3 to 21.4). 
 
Very few individuals with a Charlson Score of 6 developed PTSD (1.6, CI 0 to 
9.1).  However, individuals with a Charlson Score of 7 and 8+ developed PTSD 
at a much higher rate (16.7, CI 4.5 to 42.8 and 25.2, CI 12.1 to 46.3; 
respectively). 
 
 
 36 
 
Table2. Risk (incidence) of PTSD per 1000 person-years  
 Incidence
+
 (95% CI) 
Total 8.46 (5.98, 11.62) 
a
Age  
       <55 years 10.8 (6.6, 16.7) 
       55+ years 6.8 (4.0, 10.8) 
Race  
       Asian 24.5 (5.1, 71.7) 
       Black/African-American 11.2 (6.6, 17.7) 
       White 7.2 (4.1, 11.7) 
       
b
Other 2.1 (0.1, 11.9) 
a
AJCC Descriptive Stage  
       Stage 0 12.3 (6.3, 21.4) 
       
c
Stage I 6.0 (2.8, 11.4) 
       
d
Stage II 7.7 (3.5, 14.6) 
       
e
Stage III 10.7 (3.5, 24.9) 
       Unknown 10.4 (2.1, 30.5) 
a
Charlson Index Score  
       6 1.6 (0, 9.1) 
       7 16.7 (4.5, 42.8) 
       8+ 25.2 (12.1, 46.3) 
 
+
Incidence calculation: [(cases) ÷ (person-years)] x 1000 
a
Measured at initial breast cancer diagnosis 
b
Includes: Middle Eastern, American Indian/Native American, Unknown  
c
Includes: Stage I and Stage IEA 
d
Includes: Stage IIA, Stage IIB 
e
Includes: Stage IIIA, Stage IIIB, Stage IIIC, Stage IIINO 
 
Figure 9 shows the Kaplan-Meier estimate of cumulative incidence.  A 95% 
confidence region (shaded) is also provided.  The censoring and event times are 
shown along the x-axis, with cases set slightly lower and drawn in blue.  This plot 
provides evidence that the cumulative incidence of PTSD steadily increases in 
the study population as the time since breast cancer diagnosis increases. 
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Figure9. Kaplan-Meier Survival Curve (with censoring and events). Censoring times are shown 
along the horizontal in grey, and event times in blue. 
 
 
 
Secondary Analysis:  
To assess the influence of other factors (i.e. age, race, stage, co-morbidity) on 
the incidence of PTSD, univariate and multivariable Cox proportional-hazards 
regression models were used. 
 
In Table 3, the unadjusted risk for each of the potential risk factors was 
examined. 
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Age 
For every 10 year cross-sectional difference in baseline age, the instantaneous 
risk (hazard) of PTSD decreased by 20% in this sample (Table 3). Evidence of 
an inverse association between age and risk of PTSD was statistically significant 
(p-value = 0.05).  
 
Race 
Limited evidence was observed that women, identifying themselves as Asian, are 
at greater risk of PTSD secondary to breast cancer than their counterparts 
identifying as Whites, though the small number of cases among Asian subjects is 
severely limiting, and results are nonsignificant.  In this sample, Blacks were 1.5 
times more likely to develop PTSD than Whites, but these results were 
nonsignificant. 
 
Cancer Stage 
In this sample, individuals with Stage I breast cancer were half as likely to 
develop PTSD when compared to individuals with Stage 0 breast cancer, while 
those with Stage II cancer were at 10% lower risk than subjects at Stage 0. 
However, because these results were not statistically significant, there was little 
evidence to suggest that cancer stage and PTSD risk were associated. 
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Comorbidity 
With respect to the Charlson Score, those who scored a 7 on the index were at 4 
times the risk for developing PTSD (p=0.003) as compared to those who score a 
6 (the lowest possible score in this sample).  Additionally, those who scored 8+ 
were at 3.7 times the risk for developing PTSD (p=0.002) as compared to those 
who score a 6.  This suggests a significant positive association between 
comorbidity and PTSD risk. 
 
Table3. Univariate Regression Analysis 
Predictor variable Hazard Ratio 95% lower 
confidence limit 
95% upper 
confidence limit 
Two-sided  
P-value 
Age (decade) 0.8 0.6 1.0 0.05 
     
Race     
White reference reference reference reference 
Asian 3.3 1.0 11.3 0.06 
Black 1.5 0.8 3.0 0.21 
Other 0.3 0.03 2.2 0.23 
     
Cancer Stage     
0 reference reference reference reference 
I 0.5 0.2 1.3 0.15 
II 0.9 0.3 2.9 0.90 
III 1.6 0.5 4.4 0.41 
Unknown 0.9 0.3 3.2 0.86 
     
Charlson Score     
6 reference reference reference reference 
7 4.0 1.6 10.0 0.003 
8+ 3.7 1.6 8.5 0.002 
 
 
Age-stratified Analysis of Comorbidity 
Subsequent models focused on effects that were significant in univariate models 
(age and comorbidity). To assess preliminary evidence of interaction between the 
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two, the Charlson effect on risk stratified by age dichotomized at 55 years 
(median age of study population) was examined.  This adjusted risk is illustrated 
in Table 4.   
 
Stratifying by age in the analysis provided limited evidence of interaction; in the 
younger subcohort, the differences between Charlson subgroups were greater 
than in the older subsample. Qualitatively, however, the general pattern of 
increasing risk with increasing comorbidity held for both age groups, and the 
analysis of deviance revealed no significant difference in fit between the two 
models (p=0.18). Consequently, in subsequent analyses the potential interaction 
between age and comorbidity was discarded.   
 
Table4. Univariate Regression Analysis (comorbidity, stratified by age) 
Predictor variable Hazard Ratio 95% lower 
confidence limit 
95% upper 
confidence limit 
Two-sided  
P-value 
Charlson Score 
(<55 yrs) 
    
6 reference reference reference reference 
7 4.3 1.3 14.2 0.02 
8+ 7.5 2.6 21.2 <0.0001 
     
Charlson Score 
(55+ yrs) 
    
6 reference reference reference reference 
7 3.3 0.8 13.4 0.11 
8+ 2.9 0.7 11.0 0.13 
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Multivariable Analysis 
Table 5 illustrates the Charlson effect on the outcome adjusted for age (note: 
age is centered at 55 years).  In this model, age was treated as a continuous 
variable and Charlson Score as a categorical variable.  This model illustrates that 
for every 10 year increase in age (controlling for co-morbidity), the risk of 
developing PTSD decreased by approximately 30% (HR: 0.717); a finding that is 
statistically significant (p-value = 0.04).  As interpreted, this finding suggests that 
being older is protective against the outcome (PTSD), however, it is possible that 
this is due to survival bias. 
 
Similarly, the risk for an individual with a Charlson Score of 7 versus a Charlson 
Score of 6 is almost 7.  Meaning that, while holding age constant, individuals with 
just one other co-morbidity in addition to the breast cancer diagnosis are an 
estimated almost 7 times more likely to develop PTSD than individuals who only 
have a breast cancer diagnosis.  This finding is statistically significant (p-value = 
0.00062). 
 
Similarly, the risk for an individual with a Charlson Score of 8+ versus a Charlson 
Score of 6 is approximately 5.  In other words, while holding age constant, 
individuals with multiple co-morbidities (≥ 2) in addition to the breast cancer 
diagnosis are approximately 5 times more likely to develop PTSD than 
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individuals who only have a breast cancer diagnosis.  This finding is also highly 
statistically significant (p-value = 0.0022). 
 
Given the dis-inclusion of the potential interaction noted above, an assumption of 
this model is that the effects of age and comorbidity are additive, and that age is 
not modifying the Charlson effect (or vice versa). A model incorporating 
interaction between continuous age and comorbidity did not reveal evidence of 
interaction and in fact was less selective of such a trend than the model above 
(chi-square = 0.4822, df = 2, p-value = 0.7858). Thus the simpler model 
presented in Table 5 is preferred. 
 
 
Table5. Multivariable Analysis: Charlson Effect Adjusted for Age 
Predictor variable Hazard Ratio 95% lower 
confidence limit 
95% upper 
confidence limit 
Two-sided  
P-value 
Age, decade* 0.7 0.5 1.0 0.04 
     
Charlson Score     
6 reference reference reference reference 
7 6.7 2.3 19.8 0.00062 
8+ 5.0 1.8 14.2 0.00220 
 
*NOTE: Age is centered at 55 years 
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Sensitivity Analysis: 
Interrogation of Effect of Loss to Follow-Up 
As it was not clear whether a living subject remained under observation at the 
end of the study period, a second analysis was conducted.  The primary analysis 
reported above considered subjects to be censored either at their last observed 
visit to BMC or death, if the latter is known. The sensitivity analysis considered 
at-risk subjects to be censored either at the date of death (if known) or October 1, 
2012.  The sensitivity of the incidence estimate to these two approaches is 
reported in Tables 6 and 7. 
 
The overall incidence of PTSD was 6.59 (95% confidence interval [CI] 4.66 to 
9.04) cases per 1000 person-years of time at risk (Table 6).   
 
In Table 6, the unadjusted incidence rates, stratifying according to of each of the 
potential risk factors, is presented just as it was in Table 2 for the primary 
analysis.  In this sample, it was observed that younger individuals developed 
PTSD at a higher rate (8.5, CI 5.2 to 13.1) than older individuals (5.3, CI 3.1 to 
8.3).  Considering race, self-identified Asians developed PTSD at a higher rate 
(19.2, CI 5.2 to 13.1) than Blacks (8.8, CI 5.2 to 13.9) and Whites (5.5, CI 3.1 to 
8.9).  All of these observations are consistent with those of the primary analysis. 
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Individuals with earlier stage cancers (Stage I and Stage II) had a lower 
incidence rate (5.1, CI 2.3 to 9.7 and 6.1, CI 2.8 to 9.7; respectively) than 
individuals with later stage cancers (Stage III, IR: 7.5, CI 2.4 to 17.6).  Of note, 
the earliest stage diagnosis (Stage 0) was correlated with a higher incidence rate 
of 10.2 (CI 5.3 to 17.9).  Again, these observations are also consistent with those 
of the primary analysis. 
 
Very few individuals with a Charlson Score of 6 developed PTSD (1.2, CI 0 to 
6.5).  However, individuals with a Charlson Score of 7 and 8+ developed PTSD 
at much higher rate (13.1, CI 3.5 to 33.4 and 20.7, CI 9.9 to 38.1; respectively).  
Again, these observations are still consistent with those of the primary analysis. 
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Table6. Sensitivity Analysis:  
Risk (incidence) of PTSD per 1000 person-years 
 
 Incidence
+
 (95% CI) 
Total 6.59 (4.66, 9.04) 
a
Age  
       <55 years 8.5 (5.2, 13.1) 
       55+ years 5.3 (3.1, 8.3) 
Race  
       Asian 19.2 (4.0, 56.2) 
       Black/African-American 8.8 (5.2, 13.9) 
       White 5.5 (3.1, 8.9) 
       
b
Other 1.8 (0, 9.8) 
a
AJCC Descriptive Stage  
       Stage 0 10.2 (5.3, 17.9) 
       
c
Stage I 5.1 (2.3, 9.7) 
       
d
Stage II 6.1 (2.8, 11.6) 
       
e
Stage III 7.5 (2.4, 17.6) 
       Unknown 6.0 (1.2, 17.4) 
a
Charlson Index Score  
       6 1.2 (0, 6.5) 
       7 13.1 (3.5, 33.4) 
       8+ 20.7 (9.9, 38.1) 
 
+
Incidence calculation: [(cases) ÷ (person-years)] x 1000 
a
Measured at initial breast cancer diagnosis 
b
Includes: Middle Eastern, American Indian/Native American, Unknown  
c
Includes: Stage I and Stage IEA 
d
Includes: Stage IIA, Stage IIB 
e
Includes: Stage IIIA, Stage IIIB, Stage IIIC, Stage IIINO 
 
 
Table 7 shows the influence of other factors (i.e. age, race, stage, co-morbidity) 
on the incidence of PTSD, similar to Table 3 from the secondary analysis.  In 
Table 7, the unadjusted risk for each of the potential risk factors was examined. 
 
For every 10 year cross-sectional difference in baseline age, the instantaneous 
risk (hazard) of PTSD decreased by 30% in this sample (Table 7). Evidence of 
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an association between age and risk of PTSD was not statistically significant (p-
value = 0.08).  This was different from the secondary analysis, where the 
association between age and risk of PTSD was statistically significant (p-value = 
0.05). 
 
As compared to subjects with a Charlson score of 6, risk of PTSD for those with 
a Charlson Score of 7 was over 7 times as high (p-value = 0.0003), while it was 
over 5 times as high among those with a Charlson score of 8 (p-value = 0.001); 
suggesting significant positive association between comorbidity and PTSD risk.  
This is consistent with the findings of the secondary analysis reported previously. 
 
In general there was little evidence that race and PTSD or cancer stage and 
PTSD risk were associated held true in the sensitivity analysis. 
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Table7. Sensitivity Analysis: Univariate Regression Analysis 
Predictor variable Hazard Ratio 95% lower 
confidence limit 
95% upper 
confidence limit 
Two-sided P 
value 
Age (decade) 0.7 0.5 1.0 0.08 
     
Race     
White reference reference reference reference 
Asian 4.8 1.3 17.0 0.02 
Black 1.6 0.7 3.6 0.22 
Other 0.4 0.0 2.8 0.34 
     
Cancer Stage     
0 reference reference reference reference 
I 0.5 0.2 1.1 0.09 
II 0.5 0.2 1.2 0.13 
III 0.7 0.2 1.9 0.44 
Unknown 0.2 0.1 1.1 0.07 
     
Charlson Score     
6 reference reference reference reference 
7 7.4 2.5 21.6 0.0003 
8+ 5.4 1.9 15.0 0.0012 
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DISCUSSION 
The incidence of PTSD in breast cancer survivors has never been systematically 
studied in under-served populations who are already at risk by nature of their 
environment, such as those patients treated at Boston Medical Center.  It 
appears this is the first retrospective cohort study to look at the incidence of 
documented PTSD in breast cancer survivors in this particular subset of the 
population. 
 
The cumulative incidence was 8.46 (95% confidence interval [CI] 5.98 to 11.62) 
cases of PTSD per 1000 person-years of time.  Approximately 3% of the study 
population developed PTSD at some point during the nine-year study period.  
This is consistent, albeit on the lower end of the spectrum, with the NCI 
estimation of PTSD in cancer survivors.3 
 
Age and comorbidity (quantified by Charlson Score) were significantly associated 
with an increased risk of PTSD in this study population, while race and cancer 
stage were not found to be statistically significant.  This was surprising, but could 
be as a result of so few cases. 
 
The results indicated that age was possibly a protective factor.  This finding was 
consistent with the previous research conducted examining risk factors of PTSD 
in breast cancer survivors.38, 39 Not only did the risk of PTSD decline with age, 
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but the cox models also predict that time-to-PTSD increases with age; a finding 
that was unique to this study and would require more investigation to assert that 
it is generalizable to all younger breast cancer survivors. 
 
The results also indicated that multiple co-morbidities place a breast cancer 
survivor at higher risk of developing PTSD.  For example, an individual with a 
breast cancer diagnosis with no other co-morbidities was extremely unlikely to 
develop PTSD versus an individual with several (>2) co-morbidities.  This 
statistically significant finding was also unique to this study.  Previous research 
has not examined the effect of other physical co-morbidities on the risk of 
developing PTSD as a cancer survivor.  This would also require further 
exploration. 
 
In the multivariable model, age and Charlson Score were examined to determine 
whether either was dominating in the analysis.  It was observed that, even when 
controlling for co-morbidities, older cancer survivors still have less risk of 
developing PTSD.  Further, even when controlling for age, individuals with a 
higher Charlson Score (indicating multiple co-morbidities) were still at greater risk 
of developing PTSD.  Both the age effect and the Charlson effect were consistent 
in the data analysis.  There was some evidence that the comorbidity effect is age 
dependent (with comorbidity having greater association with risk among younger 
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subjects than among older subjects), but this finding should be considered with 
caution because there were so few cases observed. 
 
Finally, in general the observations made in the primary and secondary analyses 
held true for the sensitivity analysis.  This indicates that an alternative definition 
of risk period does not alter the results reported in the primary and secondary 
analyses. 
 
Several parallels can be drawn when comparing the results of this study with the 
results from the prospective study conducted at Columbia University Medical 
Center (CUMC), which examined a similar patient population.56 CUMC found that 
race was a statistically significant predictor when considering the risk of 
developing PTSD in cancer survivors.  Specifically, they found that women who 
identified as Black and Asian were at an increased risk as compared to women 
who identified as White.  Table 3 illustrates a similar finding in this study; 
however, this discovery was not statistically significant in this study.  The lack of 
statistical significance is likely due to the small number of cases; however this 
finding should not be completely dismissed because it has been observed in 
other studies.  This is a possible trend that warrants further investigation in future 
studies. 
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Potential Biases: 
Based on the results, it is possible that a breast cancer diagnosis is more 
traumatic for younger people.  That being said, it is also possible that survival 
bias is playing a role and older people in this sample are disproportionately 
resilient as compared to older breast cancer survivors in the general population.  
 
It is also possible that the age effect observed in this data could potentially result 
from a “cancer type” effect.  It has been documented that younger women tend to 
be diagnosed with more aggressive forms of breast cancer.48 It is possible that 
younger individuals with these more aggressive forms of breast cancer may have 
a more traumatic experience.  This may be increasing these individuals’ risk of 
PTSD. 
 
Limitations: 
There are several limitations to this project.  The first limitation is within the study 
design itself.  The data was collected in a retrospective fashion and was 
extracted from an already existing pool of data.  Therefore, the investigator was 
at the mercy of the data available in the data set.  This could have potentially 
affected the quality and accuracy of the data reported as the investigator was 
unable to ensure consistency in reporting.  As a result, the conclusions of this 
study may be based off of an incomplete data set and caution should be used 
when interpreting these findings. 
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Second, the diagnosis of PTSD was obtained via ICD-9 codes in the medical 
record.  Thus, it is unknown if any subjects may have gone undiagnosed by a 
medical professional, were coded improperly, or exhibited characteristics of sub-
syndromal PTSD.  This may have resulted in an underrepresentation of PTSD 
cases in the study population. 
 
Third, while every breast cancer patient was included who was eligible during the 
pre-defined nine year study period, the number of cases was extremely limited.  
There were only 38 cases of PTSD identified out of the 1301 breast cancer 
patients diagnosed over the nine year study period.  This means that caution 
should be used when making any assertions about the analysis of this data.  A 
larger sample would have been preferable because it may have resulted in a 
more stable estimate of the population parameters. 
 
Fourth, individuals who had a pre-cancer diagnosis of PTSD were excluded from 
the study cohort.  While the original intent was to look at the incidence of PTSD 
that manifested after a breast cancer diagnosis, exacerbations of PTSD 
symptoms in individuals who were already diagnosed were not captured.  By not 
considering individuals with pre-cancer PTSD, a full picture of all individuals who 
are diagnosed with both conditions cannot be ascertained. 
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Finally, the results of this study can only be generalized to populations similar to 
those treated at Boston Medical Center.  While that was the original intent of the 
study, it also becomes a limitation if an attempt is made to compare the data to 
other heterogeneous populations.  Other homogenous populations should also 
be studied before one is able to make solid statements surrounding the incidence 
of PTSD in breast cancer patients. 
 
Future Directions: 
The results of this study support the need for further investigation.  Individuals in 
the background population (without a breast cancer diagnosis) were not followed 
to document their PTSD experience.  While it was beyond the scope of this 
project to determine the risk of PTSD attributable to breast cancer diagnoses, 
this information would be useful for comparison.  The analysis will need to be 
expanded for future projects to determine the risk of PTSD attributable to breast 
cancer. 
 
A prospective cohort observational study in a similar population would also be 
useful to allow for more control over variables collected and analyzed.  For 
example, it would be interesting to see if the type of treatment (i.e. surgery, 
radiation, system therapy, combination therapy, palliative care, etc.) had any 
impact on a breast cancer patient’s risk of developing PTSD.  Additionally, a 
prospective study would be adequately powered, i.e. large enough to observe 
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many more PTSD cases than were observed in this retrospective study, thus 
making subgroup and covariable analyses more realistic. 
 
The data from this study also supports the need for a breast cancer-specific 
PTSD screening tool and treatment protocol to be developed and implemented at 
Boston Medical Center.  In addition, future interventional studies could be 
designed to investigate which screening tools and treatment protocols would be 
most effective for this particular patient population. 
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CONCLUSIONS 
The results of the study support that adult breast cancer patients treated at 
Boston Medical Center are at risk for developing PTSD.  An estimated 3% of 
female breast cancer survivors in the BMC population will develop PTSD with 
nine years of breast cancer diagnosis exposure.  Additionally, these data provide 
limited evidence that younger age (< 55 years) and comorbidity (Charlson Index 
Score ≥ 7) are risk factors for PTSD incidence in the BMC population.   
 
These results underscore the need for both further descriptive studies and 
interventions aimed at early identification and treatment of PTSD in breast cancer 
survivors. 
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APPENDIX 
 
Charlson Comorbidity Index Scoring System22 
 
 
Score 
 
Condition 
 
 
1 
 
Myocardial infarction (history, not ECG changes only) 
 Congestive heart failure 
 Peripheral vascular disease (includes aortic aneurysm ≥6 cm) 
 Cerebrovascular disease: CVA with mild or no residua or TIA 
 Dementia 
 Chronic pulmonary disease 
 Connective tissue disease 
 Peptic ulcer disease 
 Mild liver disease (without portal hypertension, includes chronic hepatitis) 
 Diabetes without end-organ damage (excludes diet-controlled alone) 
2 Hemiplegia 
 Moderate to severe renal disease 
 Diabetes w/ end-organ damage (retinopathy, neuropathy, nephropathy, or brittle diabetes) 
 Tumor without metastases (exclude if >5 y from diagnosis) 
 Leukemia (acute or chronic) 
 Lymphoma  
3 Moderate or severe liver disease 
6 Metastatic solid tumor 
 AIDS (not just HIV positive) 
 
Abbreviations: ECG, electrocardiogram; CVA, cerebrovascular accident; TIA, transient ischemic 
attack; AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus 
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